Evaluation of Effectiveness and Safety of Everolimus-Eluting Stents in Routine Clinical Practice
Latest Information Update: 20 Nov 2015
Price :
$35 *
At a glance
- Drugs Everolimus (Primary) ; Sirolimus
- Indications Coronary artery disease
- Focus Adverse reactions; Therapeutic Use
- 10 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 14 May 2011 New trial record